Maplight Therapeutics (NASDAQ:MPLT) CEO Sells $420,937.80 in Stock

by · The Cerbat Gem

Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) CEO Christopher Kroeger sold 13,980 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $30.11, for a total transaction of $420,937.80. Following the completion of the sale, the chief executive officer owned 1,512,329 shares of the company’s stock, valued at approximately $45,536,226.19. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maplight Therapeutics Stock Up 9.8%

Maplight Therapeutics stock traded up $2.69 during trading on Monday, reaching $30.09. The company had a trading volume of 288,241 shares, compared to its average volume of 312,441. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $33.28. The business’s 50 day moving average price is $23.27. The stock has a market capitalization of $1.28 billion and a price-to-earnings ratio of -0.76.

Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Equities analysts expect that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on MPLT. HC Wainwright began coverage on shares of Maplight Therapeutics in a report on Monday, May 4th. They issued a “buy” rating and a $45.00 target price for the company. Wall Street Zen downgraded shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating for the company. Needham & Company LLC started coverage on shares of Maplight Therapeutics in a research note on Wednesday, April 8th. They set a “buy” rating and a $37.00 price objective for the company. Finally, Weiss Ratings started coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They set a “sell (e)” rating for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maplight Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $34.43.

Get Our Latest Report on MPLT

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Fcpm Iii Services B.V. purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $49,154,000. Goldman Sachs Group Inc. purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $17,060,000. Finally, 5AM Venture Management LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $16,687,000.

About Maplight Therapeutics

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

Featured Stories